HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer—A study of two hundred cases

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

Michael F. Press, Leslie Bernstein, P. Thomas et al. · Journal of Clinical Oncology · 1997 · 810 citations

Medicine, Molecular Biology, Oncology +14

Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: A Direct Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry

Giovanni M. Pauletti, Suganda Dandekar, Hong-Mei Rong et al. · Journal of Clinical Oncology · 2000 · 685 citations

Medicine, Cancer Biology, Oncology +17

HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer Tissues

Marilyn A. Owens, Bruce Horten, Moacyr M. Da Silva · Clinical Breast Cancer · 2004 · 653 citations

Medicine, Molecular Biology, Oncology +14

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

Giovanni M. Pauletti, William Godolphin, M F Press et al. · PubMed · 1996 · 560 citations

Medicine, Molecular Biology, Oncology +15

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

R. Seshadri, F A Firgaira, DJ Horsfall et al. · Journal of Clinical Oncology · 1993 · 535 citations

Medicine, Oncology, Pathology +17